The company's drug candidate Xanamem is designed to block the production of cortisol in the brain, which offers a promising new approach to slowing cognitive decline. Actinogen Medical is conducting an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease, with results expected in early 2019. Xanamem has been studied in more than 300 volunteers and patients, showing statistically significant improvements in working memory and attention in healthy older volunteers and clinically significant improvements in patients with biomarker-positive mild AD. The company is moving forward with double-blind, randomized, placebo-controlled Phase 2 trials in cognitive impairment in Alzheimer’s Disease and Depression to further confirm and characterize Xanamem’s therapeutic potential.